Description | Pamapimod (R-1503, Ro4402257) is a novel, selective inhibitor of p38 mitogen-activated protein kinase. It inhibits p38α and p38β enzymatic activity with IC50 values of 0.014±0.002 and 0.48± 0.04 microM, respectively with no activity against p38delta or p38gamma isoforms. |
---|
Targets | p38α [1](Cell-free assay) | p38β [1](Cell-free assay) | 0.014 μM | 0.48 μM |
|
---|
In vitro | Pamapimod inhibited p38, but inhibition of JNK was not detected. Pamapimod also inhibited lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) α production by monocytes, interleukin (IL)-1β production in human whole blood, and spontaneous TNFα production by synovial explants from RA patients[1]. |
---|
In vivo | In murine collagen-induced arthritis, pamapimod reduced clinical signs of inflammation and bone loss at 50 mg/kg or greater. In a rat model of hyperalgesia, pamapimod increased tolerance to pressure in a dose-dependent manner, suggesting an important role of p38 in pain associated with inflammation. Pamapimod suppresses spontaneous production of TNFα by synovial explants from RA patients. LPS- and TNFα-stimulated production of TNFα and IL-6 in rodents also was inhibited by pamapimod[1]. |
---|
Selleck Chemicals一直专注于生命科学领域高端试剂的开发与研究,旨在以最优价格为客户提供最优质的科研试剂服务。我们的产品包括抗体,重组蛋白,干扰rna,多肽,小分子激酶抑制剂等。Selleck Chemicals拥有一支热情与活力并存,经验与技术兼备的技术支持与客户服务团队,凭借在生命科学领域的多年研发经验,公司与多达2万多个客户建立了长期稳定的合作关系,其中包括世界各大制药厂,生物科技公司,医院及各大临床诊断实验室,世界各著名高校、研究所以及政府机关。